Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

PHASE3CompletedINTERVENTIONAL
Enrollment

1,065

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Bone LossBreast Cancer
Interventions
DRUG

Zoledronic acid

Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.

DRUG

Letrozole

Letrozole tablets 2.5 mg/day taken orally for 5 years.

Trial Locations (106)

100

Novartis Investigative Site, Taipei

105

Novartis Investigative Site, Taipei

110

Novartis Investigative Site, Seoul

112

Novartis Investigative Site, Taipei

137

Novartis Investigative Site, Seoul

138

Novartis Investigative Site, Seoul

139

Novartis Investigative Site, Seoul

500

Novartis Investigative Site, Chang-hua

10400

Novartis Investigative Site, Bangkok

33081

Novartis Investigative Site, Aviano

40002

Ratchathew, Khonkaen

50139

Novartis Investigative Site, Florence

88100

Novartis Investigative Site, Catanzaro

Unknown

Novartis Investigative Site, Buenos Aires

Novartis Investigative Site, Rosario Santa Fe

Novartis Investigative Site, New South Wales

Novartis Investigative Site, Perth

Novartis Investigative Site, South Australia

Novartis Investigative Site, Victoria

Novartis Investigative Site, Bonheiden

Novartis Investigative Site, Brasschaat

Novartis Investigative Site, Brussels

Novartis Investigative Site, Leuven

Novartis Investigative Site, Wilrijk

Novartis Investigative Site, Porto Alegre

Novartis Investigative Site, São Paulo

Novartis Investigative Site, Santiago

Novartis Investigative Site, Beijing

Novartis Investigative Site, Shanghai

Novartis Investigative Site, Medellín

Novartis Investigative Site, Nemocnice

Novartis Investigative Site, Cairo

Novartis Investigative Site, Pori

Novartis Investigative Site, Turku

Novartis Investigative Site, Bordeaux

Novartis Investigative Site, Le Havre

Novartis Investigative Site, Montpellier

Novartis Investigative Site, Poitiers

Novartis Investigative Site, Saint-Cloud

Novartis Investigative Site, Augsberg

Novartis Investigative Site, Berlin

Novartis Investigative Site, Ebersberg

Novartis Investigative Site, Frankfurt

Novartis Investigative Site, Halberstadt

Novartis Investigative Site, Hamburg

Novartis Investigative Site, Hoyerswerda

Novartis Investigative Site, Kassel

Novartis Investigative Site, Kiel

Novartis Investigative Site, Munich

Novartis Investigative Site, München

Novartis Investigative Site, Neunkirchen

Novartis Investigative Site, Rostock

Novartis Investigative Site, Stadthagen

Novartis Investigative Site, Stendal

Novartis Investigative Site, Trier

Novartis Investigative Site, Tübingen

Novartis Investigative Site, Wiesbaden

Novartis Investigative Site, Guatemala City

Novartis Investigative Site, Hong Kong

Novartis Investigative Site, Ancona

Novartis Investigative Site, Bergamo

Novartis Investigative Site, Genova

Novartis Investigative Site, Meldola

Novartis Investigative Site, Modena

Novartis Investigative Site, Orbassano Torino

Novartis Investigative Site, Perugia

Novartis Investigative Site, Torino

Novartis Investigative Site, Varese

Novartis Investigative Site, Distrito Federal

Novartis Investigative Site, Almere Stad

Novartis Investigative Site, Arnhem

Novartis Investigative Site, Ede

Novartis Investigative Site, Eindhoven

Novartis Investigative Site, Hoogeveen

Novartis Investigative Site, Leiden

Novartis Investigative Site, Nijmegen

Novartis Investigative Site, The Hague

Novartis Investigative Site, Utrecht

Novartis Investigative Site, Hamilton

Novartis Investigative Site, Wellington

Novartis Investigative Site, Jesus Maria

Novartis Investigative Site, La Victoria

Novartis Investigative Site, Surquillo

Novartis Investigative Site, Cebu City

Novartis Investigative Site, Quezon City

Novartis Investigative Site, Coimbra

Novartis Investigative Site, Gyeonggi-do

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Córdoba

Novartis Investigative Site, Gea de Albarracín

Novartis Investigative Site, Ibáñez

Novartis Investigative Site, la Masó

Novartis Investigative Site, Villaroel

Novartis Investigative Site, Bern

Novartis Investigative Site, Locarno

Novartis Investigative Site, Lugano

Novartis Investigative Site, Bangkok

Novartis Investigative Site, Birmingham

Novartis Investigative Site, Essex

Novartis Investigative Site, Manchester

Novartis Investigative Site, New Castle Upon Tyne

Novartis Investigative Site, Nottingham

Novartis Investigative Site, Plymouth

Novartis Investigative Site, Sheffield

Novartis Investigative Site, Swansea

Novartis Investigative Site, Caracas

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00171340 - Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer. | Biotech Hunter | Biotech Hunter